Molecule
Lamivudine is a hepatitis B virus nucleoside analog reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is available as tablets and oral solution. MedsAcross supplies Lamivudine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. Limitations of Use: • The dosage of this product is for HIV‑1 and not for HBV. EPIVIR is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection.
Source: US FDA prescribing information
Lamivudine is an antiretroviral agent.
Source: US FDA prescribing information
• Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily. • Pediatric Patients Aged 3 Months and Older: Administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily. • Patients with Renal Impairment: Doses of EPIVIR must be adjusted in accordance with renal function.
Source: US FDA prescribing information
EPIVIR is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. EPIVIR is contraindicated in patients with previous hypersensitivity reaction to lamivudine.
Source: US FDA prescribing information
Boxed warning (exacerbations of hepatitis b and different formulations of epivir): Exacerbations of Hepatitis B Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued EPIVIR. • Co-infected HIV‑1/HBV Patients: Emergence of lamivudine-resistant HBV variants associated with lamivudine‑containing antiretroviral regimens has been reported. • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. • Pancreatitis: Use with caution in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Discontinue treatment as clinically appropriate.
Source: US FDA prescribing information
The following adverse reactions are discussed in other sections of the labeling: • Exacerbations of hepatitis B. • Lactic acidosis and severe hepatomegaly with steatosis. • Pancreatitis. • Immune reconstitution syndrome. • The most common reported adverse reactions (incidence greater than or equal to 15%) in adults were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough. • The most common reported adverse reactions (incidence greater than or equal to 15%) in pediatric subjects were fever and cough.
Source: US FDA prescribing information
Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations, when possible, avoid chronic coadministration. Drugs Inhibiting Organic Cation Transporters Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim). No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine. Sorbitol Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine.
Source: US FDA prescribing information
Store EPIVIR tablets at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Store in tightly closed bottles at 25°C (77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Lamivudine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lamivudine 150 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lamivudine 300 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lamivudine 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lamivudine 10 mg/mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Epivir 10 mg/mL oral solutionOral | ViiV Healthcare | US FDA | Available on request |
| Epivir 150 mg tabletOral | ViiV Healthcare | US FDA | Available on request |
| Epivir 300 mg tabletOral | ViiV Healthcare | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Lamivudine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Lamivudine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lamivudine, including Epivir.
Yes. The US FDA first approved Lamivudine on 17 November 1995, according to Drugs@FDA.
Yes. Lamivudine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Lamivudine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lamivudine is classified under ATC code J05AF05 (Lamivudine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.